{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:09:07Z","timestamp":1780585747235,"version":"3.54.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"DOI":"10.7759\/cureus.94770","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:03:44Z","timestamp":1760688224000},"source":"Crossref","is-referenced-by-count":1,"title":["Effect of Tirzepatide in an Adolescent With Early-Onset Obesity, Hyperphagia, and Type 2 Diabetes"],"prefix":"10.7759","author":[{"given":"Bakht Noor","family":"Khurshid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukasha","family":"Moazzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Dimitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2573","article-title":"Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline","volume":"102","author":"Styne DM","year":"2017","unstructured":"Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017, 102:709-57. 10.1210\/jc.2016-2573","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl SE","year":"2023","unstructured":"Hampl SE, Hassink SG, Skinner AC, et al.. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023, 151:10.1542\/peds.2022-060640","journal-title":"Pediatrics"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2244188.094","article-title":"Genetic obesity: an update with emerging therapeutic approaches","volume":"27","author":"Sohn YB","year":"2022","unstructured":"Sohn YB. Genetic obesity: an update with emerging therapeutic approaches. Ann Pediatr Endocrinol Metab. 2022, 27:169-75. 10.6065\/apem.2244188.094","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz A","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025, 138:934-40. 10.1016\/j.amjmed.2025.01.021","journal-title":"Am J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-13-0414","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS","volume":"221","author":"van Bloemendaal L","year":"2014","unstructured":"van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014, 221:T1-16. 10.1530\/JOE-13-0414","journal-title":"J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2436595","article-title":"Tirzepatide for overweight and obesity management","volume":"26","author":"Hamza M","year":"2025","unstructured":"Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025, 26:31-49. 10.1080\/14656566.2024.2436595","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.aed.2025.03.004","article-title":"Successful treatment of hypothalamic obesity with tirzepatide","volume":"12","author":"Brijmohan S","year":"2025","unstructured":"Brijmohan S, Mullally JA. Successful treatment of hypothalamic obesity with tirzepatide. AACE Endocrinol Diabetes. 2025, 12:30-3. 10.1016\/j.aed.2025.03.004","journal-title":"AACE Endocrinol Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256514","article-title":"Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon","volume":"14","author":"Roth CL","year":"2023","unstructured":"Roth CL, Zenno A. Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon. Front Endocrinol (Lausanne). 2023, 14:1256514. 10.3389\/fendo.2023.1256514","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100104","article-title":"Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: a narrative review","volume":"10","author":"Chartoumpekis DV","year":"2024","unstructured":"Chartoumpekis DV, Habeos EE, Psilopanagioti A. Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: a narrative review. Obes Pillars. 2024, 10:100104. 10.1016\/j.obpill.2024.100104","journal-title":"Obes Pillars"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/414233-effect-of-tirzepatide-in-an-adolescent-with-early-onset-obesity-hyperphagia-and-type-2-diabetes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:03:44Z","timestamp":1760688224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/414233-effect-of-tirzepatide-in-an-adolescent-with-early-onset-obesity-hyperphagia-and-type-2-diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.94770","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}